

Press release

DICOT

Dicot broadens the testing of the drug candidate LIB-01: conducts studies of premature ejaculation

Press release: Uppsala, February 5, 2021. The main focus for the potency drug developer Dicot has so far been on studying the effect on erectile dysfunction in its drug candidate LIB-01. In accordance with the company's overall strategy, testing is now being broadened. Therefore, studies of premature ejaculation have started together with the world-leading contract research organisation that has participated in preclinical testing of several renowned compounds in this field.

Dicot's goal for its drug candidate LIB-01 (formerly Libiguin) is to be the leading treatment for erectile dysfunction and premature ejaculation. So far, research has revolved mostly around erectile dysfunction and this work is progressing in accordance with the company's development plan. Testing is now being extended by including premature ejaculation to assess the effect of the drug candidate in animal models relevant to this indication.

The first study is already initiated and aims to evaluate the effect of LIB-01 treatment on ejaculation in anesthetized rats. The results will form the basis for the next step when the company enters more advanced models where the animals' behaviour will be studied in more detail. Results are expected to be announced later in 2021.

The studies are carried out in collaboration with Pelvipharm SAS, a world-leading preclinical contract Research Organisation specializing in the evaluation of sexual dysfunctions and which has collaborated with several leading big pharmaceutical companies in this field.

Premature ejaculation is one of the most common form of sexual dysfunction. Epidemiological studies indicate that 18-30% of all men are burdened by premature ejaculation, that's about every fourth man. The global market was estimated at approximately USD 1.5 billion in 2018 and is expected to grow even more in the coming years. At present, there is only one approved drug for the treatment of premature ejaculation on the market and very few clinical trials with other drug candidates are ongoing.

Premature ejaculation may be considered a relatively immature market where there is limited help available for the men and couples who are affected. If our studies prove LIB-01 to be an effective

treatment, we can both help those suffering from this condition and at the same time take a significant share of the world market," says Dicot's CEO Göran Beijer.

For further information, please contact:

Göran Beijer, CEO

Tel: +46 70-663 60 09

Email: goran.beijer@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01 (formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion.

Research and development is conducted under own auspices up to phase 1 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,800 shareholders. For more information, please visit: www.dicot.se